Allopregnanolone Is Required for Prepulse Inhibition Deficits Induced by D1 Dopamine Receptor Activation

    June 2019 in “ Psychoneuroendocrinology ”
    Laura J. Mosher, Roberto Cadeddu, Sabrina Yen … Marco Bortolato
    Studysummary This study found that in rodent models, the ability of D1 dopamine receptor activation to impair sensory gating is facilitated by 5α-reductase type 1, which produces allopregnanolone.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on sciencedirect.com →
    Discuss this study in the Community →

    Research cited in this study 14

    1. Repurposing Steroidogenesis Inhibitors for the Therapy of Neuropsychiatric Disorders: Promises and Caveats Neuropharmacology · 2018
    2. Steroid 5α-Reductase 2 Deficiency Leads to Reduced Dominance-Related and Impulse-Control Behaviors Psychoneuroendocrinology · 2018
    3. Allopregnanolone Mediates the Exacerbation of Tourette-Like Responses by Acute Stress in Mouse Models Scientific reports · 2017
    4. The Neurosteroidogenic Enzyme 5α-Reductase Modulates the Role of D1 Dopamine Receptors in Rat Sensorimotor Gating Psychoneuroendocrinology · 2015
    5. Adverse Effects of 5α-Reductase Inhibitors: What Do We Know, Don't Know, and Need to Know? Reviews in Endocrine and Metabolic Disorders · 2015
    6. Inhibition Of 5α-Reductase Attenuates Behavioral Effects Of D1-, But Not D2-Like Receptor Agonists In C57BL/6 Mice Psychoneuroendocrinology · 2012
    7. Inhibition of 5α-Reductase in the Nucleus Accumbens Counters Sensorimotor Gating Deficits Induced by Dopaminergic Activation Psychoneuroendocrinology · 2011
    8. A Preliminary Study of Finasteride in Tourette Syndrome Movement Disorders · 2011
    9. Steroid 5α-Reductase as a Novel Therapeutic Target for Schizophrenia and Other Neuropsychiatric Disorders Current Pharmaceutical Design · 2011
    10. Improvement of General Symptoms in a Chronic Psychotic Patient Treated with Finasteride: Case Report Pharmacopsychiatry · 2008
    11. Antipsychotic-Like Properties of 5-Alpha-Reductase Inhibitors Neuropsychopharmacology · 2008
    12. Treatment of Tourette’s Syndrome With Finasteride American Journal of Psychiatry · 2007
    13. MK-386, an Inhibitor of 5α-Reductase Type 1, Reduces Dihydrotestosterone Concentrations in Serum and Sebum Without Affecting Dihydrotestosterone Concentrations in Semen The Journal of Clinical Endocrinology & Metabolism · 1997
    14. Four-Amino Acid Segment in Steroid 5 Alpha-Reductase 1 Confers Sensitivity to Finasteride, a Competitive Inhibitor Journal of Biological Chemistry · 1992